Mechanism of Action and Clinical Effect of BI 655130 in Patients With Fistulizing Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Spesolimab (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors Boehringer Ingelheim
- 16 Sep 2019 Planned End Date changed from 30 Oct 2020 to 31 Mar 2021.
- 16 Sep 2019 Planned primary completion date changed from 30 Oct 2020 to 31 Mar 2021.
- 06 Feb 2019 Status changed from not yet recruiting to recruiting.